Elucidating the mechanism that initiates cancer cachexia
The new findings could lead to new therapeutics and a method to diagnose pancreatic cancer earlier, improving its prognosis.
List view / Grid view
The new findings could lead to new therapeutics and a method to diagnose pancreatic cancer earlier, improving its prognosis.
The discovery that genomic deletions cause altBRAFs can help develop new therapies to overcome drug resistance in BRAF-mutant melanoma.
In this Q&A, Associate Professor Dr Mete Civelek shares insights from the University of Virginia’s exciting recent study identifying several potential therapeutic targets for accelerating translational research in cardiovascular disease treatment, with a focus on proteins associated with the extracellular matrix (ECM) secretion by smooth muscle cells (SMCs).
In this Q&A, Curve Therapeutic’s Chief Scientific Officer Professor Ali Tavassoli discusses how dual HIF inhibition could combat solid tumours.
IFNβ could be developed into a new therapy, following an improved understanding of how innate immunity affects the brain during chronic HIV infection.
In this Q&A, Dr Nicholas Waters, Head of R&D at IRLAB, shares how three compounds, including IRLABs Mesdopetam and an experimental dopamine D3 receptor antagonist, could reverse features associated with the psychosis-like state of Parkinson’s disease.
Researchers find how antibiotic treatments influence the microbiota, providing new strategies for preventing antibiotic-induced damage.
The discovery that one missing copy of MUTYH could increase the risk of cancers may lead to therapeutics against solid tumours.
Mutation in two copies of the IKBKB gene leads to abnormal function of regulatory T cells, causing psoriatic arthritis.
New understanding of the CRC and its interaction with STAT3 could lead to novel therapeutics and combination strategies.
Researchers have discovered two distinct lineages of Fusobacterium nucleatum, which has great implications for colorectal cancer screening and therapeutics.
In this Q&A, Aki Ko, CEO and co-founder of Elixirgen Therapeutics, elucidates how their new mRNA technology could potentially restore muscle function in those suffering from Duchenne muscular dystrophy.
The Organoid Group have discovered a link between FBXW7 mutations and the EGFR signalling pathway, which could improve colorectal cancer treatments.
Scientists have examined gene activity in mice models, noting important indicators of liver disease severity which may be used as therapeutic strategies.
Inhibiting the LDHA and GOT1 enzymes could prevent cancer cells’ ability to produce energy, without affecting healthy cells.